{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pomalidomide&page=5", "query": { "intervention": "pomalidomide", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 204, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pomalidomide&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pomalidomide&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T18:41:59.813Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01432600", "title": "Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myeloma" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2011-11", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2017-05-23", "last_synced_at": "2026-10-21T18:41:59.813Z", "location_count": 3, "location_summary": "San Francisco, California • Tampa, Florida • New York, New York", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01432600" }, { "nct_id": "NCT04700176", "title": "A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "All-trans retinoic acid", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hackensack Meridian Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2022-05-02", "completion_date": "2023-11-15", "has_results": true, "last_update_posted_date": "2025-02-25", "last_synced_at": "2026-10-21T18:41:59.813Z", "location_count": 1, "location_summary": "Hackensack, New Jersey", "locations": [ { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04700176" }, { "nct_id": "NCT00833833", "title": "MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 259, "start_date": "2008-06", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2016-04-27", "last_synced_at": "2026-10-21T18:41:59.813Z", "location_count": 14, "location_summary": "Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00833833" }, { "nct_id": "NCT02287558", "title": "Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hereditary Hemorrhagic Telangiectasia", "Idiopathic Vascular Ectasia" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2015-01-27", "completion_date": "2019-06-01", "has_results": false, "last_update_posted_date": "2020-07-15", "last_synced_at": "2026-10-21T18:41:59.813Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02287558" }, { "nct_id": "NCT03170882", "title": "A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed and/or Refractory Multiple Myeloma" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2017-08-01", "completion_date": "2021-11-26", "has_results": true, "last_update_posted_date": "2022-12-20", "last_synced_at": "2026-10-21T18:41:59.813Z", "location_count": 10, "location_summary": "Fayetteville, Arkansas • Santa Rosa, California • Boca Raton, Florida + 7 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03170882" }, { "nct_id": "NCT05651932", "title": "A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Myeloma", "Myeloma Multiple" ], "interventions": [ { "name": "Cohort A1 & A2: KTX-1001", "type": "DRUG" }, { "name": "Cohort B1 & B2: KTX-1001+Mezigdomide", "type": "DRUG" }, { "name": "Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)", "type": "DRUG" }, { "name": "Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "K36 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2023-02-22", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-21T18:41:59.813Z", "location_count": 17, "location_summary": "San Francisco, California • Jacksonville, Florida • Miami, Florida + 13 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05651932" }, { "nct_id": "NCT04068597", "title": "Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Haematological Malignancy", "Acute Myeloid Leukemia", "Non Hodgkin Lymphoma", "Multiple Myeloma", "Higher-risk Myelodysplastic Syndrome", "Peripheral T Cell Lymphoma" ], "interventions": [ { "name": "CCS1477", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Elranatamab", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CellCentric Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2019-08-09", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-10-21T18:41:59.813Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Indianapolis, Indiana • Bethesda, Maryland + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04068597" }, { "nct_id": "NCT03143985", "title": "Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Vactosertib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Koen van Besien", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2017-07-21", "completion_date": "2022-09-01", "has_results": false, "last_update_posted_date": "2024-05-24", "last_synced_at": "2026-10-21T18:41:59.813Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03143985" }, { "nct_id": "NCT01807286", "title": "Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloma" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Questionnaires", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2014-01", "completion_date": "2016-02", "has_results": false, "last_update_posted_date": "2016-05-13", "last_synced_at": "2026-10-21T18:41:59.813Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01807286" }, { "nct_id": "NCT01997840", "title": "ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2014-03-01", "completion_date": "2024-02-29", "has_results": true, "last_update_posted_date": "2025-03-04", "last_synced_at": "2026-10-21T18:41:59.813Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Cleveland, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01997840" } ] }